Kelly West Fitzpatrick MD (She/Her)

Hematologic Oncology

Hematologist/Oncologist, Regional Cancer Care Associates, LLC and JTCC; HOPE Tower: Hackensack Meridian Health Jersey Shore University Medical Center

Join to view full profile

19 Davis AvenueHope Tower - 2nd FloorNeptune, NJ 07753
Phone+1 732-897-3530
Fax+1 732-776-4109

Dr. Fitzpatrick is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fitzpatrick's full profile Already have an account?

Summary

Dr. Kelly Fitzpatrick is a hematologist-oncologist with Regional Cancer Care Associates in NJ, primarily as part of the HOPE tower Leukemia and BMT team at Hackensack Meridian Jersey Shore University Medical Center but also affiliated with the John Theurer Cancer Center in Hackensack since Nov 2021. Previously, she worked as an academic hematologist at MedStar Washington Hospital Center in DC.

Education & Training

MedStar Health Georgetown UniversityFellowship, Hematology and Medical Oncology, 2009 - 2012
MedStar Health Georgetown University/Georgetown HospitalResidency, Internal Medicine, 2006 - 2009
Georgetown University School of MedicineClass of 2006

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NJ State Medical License 2021 - 2027
DC State Medical License 2006 - 2026
MD State Medical License 2012 - 2022
VA State Medical License 2006 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification MEDSEEK Empower, SymphonyCare, LLC, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2013-2014, 2016-2017

Publications & Presentations

PubMed

16 citations
Efficacy and Safety of Direct-Acting Oral Anticoagulants (DOACs) in the Overweight and Obese.
Kimberley Doucette, Hira Latif, Anusha Vakiti, Eshetu Tefera, Bhavisha A Patel
Advances in Hematology. 2020-05-23
17 citations
Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab.
Anusha Vakiti, Daulath Singh, Ravi Pilla, Muhamad Alhaj-Moustafa, Kelly W. Fitzpatrick
Journal of Oncology Pharmacy Practice. 2019-06-01
9 citations
DA-EPOCH-R for post-transplant lymphoproliferative disorders
Christin B. DeStefano, Vera Malkovska, Hind Rafei, Aarthi Shenoy, Kelly W. Fitzpatrick
European Journal of Haematology. 2017-09-01

Journal Articles

90Y-Epratuzumab, a Humanized Yttrium-Radiolabeled Anti-CD22mAb for the Potential Treatment of Non-Hodgkin's Lymphoma.
KW Fitzpatrick, BD Cheson, Thomas Reuters Drug Profiles, 2/20/2012